[go: up one dir, main page]

BR9509890A - Polipeptídeo sequencia de dna ou rna vetor célula hospedeira e processo para produzir um polipeptídeo - Google Patents

Polipeptídeo sequencia de dna ou rna vetor célula hospedeira e processo para produzir um polipeptídeo

Info

Publication number
BR9509890A
BR9509890A BR9509890A BR9509890A BR9509890A BR 9509890 A BR9509890 A BR 9509890A BR 9509890 A BR9509890 A BR 9509890A BR 9509890 A BR9509890 A BR 9509890A BR 9509890 A BR9509890 A BR 9509890A
Authority
BR
Brazil
Prior art keywords
polypeptide
dna
producing
host cell
cell vector
Prior art date
Application number
BR9509890A
Other languages
English (en)
Inventor
Amanda Elizabeth Inn Proudfoot
Timothy Nigel Carl Wells
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9424835.8A external-priority patent/GB9424835D0/en
Priority claimed from GBGB9512319.6A external-priority patent/GB9512319D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR9509890A publication Critical patent/BR9509890A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR9509890A 1994-12-08 1995-12-07 Polipeptídeo sequencia de dna ou rna vetor célula hospedeira e processo para produzir um polipeptídeo BR9509890A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9424835.8A GB9424835D0 (en) 1994-12-08 1994-12-08 Substances and their uses
GBGB9512319.6A GB9512319D0 (en) 1995-06-16 1995-06-16 Substances and their uses
PCT/GB1995/002861 WO1996017935A2 (en) 1994-12-08 1995-12-07 Rantes peptide and fragments and compositions comprising it for treatment of inflammation

Publications (1)

Publication Number Publication Date
BR9509890A true BR9509890A (pt) 1997-12-30

Family

ID=26306133

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9509890A BR9509890A (pt) 1994-12-08 1995-12-07 Polipeptídeo sequencia de dna ou rna vetor célula hospedeira e processo para produzir um polipeptídeo

Country Status (15)

Country Link
US (2) US6159711A (pt)
EP (1) EP0796330A1 (pt)
JP (1) JPH10510151A (pt)
CN (1) CN1087346C (pt)
AU (1) AU688641B2 (pt)
BR (1) BR9509890A (pt)
CA (1) CA2207036A1 (pt)
CZ (1) CZ290850B6 (pt)
FI (1) FI972433A7 (pt)
HU (1) HU221089B1 (pt)
MX (1) MX9703889A (pt)
NO (1) NO972620L (pt)
NZ (1) NZ296570A (pt)
PL (1) PL182786B1 (pt)
WO (1) WO1996017935A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU688641B2 (en) * 1994-12-08 1998-03-12 Glaxo Group Limited Rantes peptide and fragments and compositions comprising it for treatment of inflammation
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
EP0972043A1 (en) * 1996-09-25 2000-01-19 British Biotech Pharmaceuticals Limited Human rantes mutants incapable of aggregate formation
US6852508B1 (en) 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
IT1291353B1 (it) * 1997-05-12 1999-01-07 San Raffaele Centro Fond Peptidi con attivita' antivirale
US6168784B1 (en) 1997-09-03 2001-01-02 Gryphon Sciences N-terminal modifications of RANTES and methods of use
EP0906954A1 (en) * 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
MXPA00003885A (es) * 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
DE69832216T2 (de) * 1997-12-23 2006-05-24 Fondazione Centro San Raffaele Del Monte Tabor RANTES-Mutanten und therapeutische Anwendungen davon
US6121023A (en) * 1998-01-22 2000-09-19 Akzo Nobel N.V. Isothermal transcription based assay for the detection and quantification of the chemokine rantes
EP1000626A1 (en) * 1998-09-18 2000-05-17 Applied Research Systems ARS Holding N.V. Chemokine receptor antagonist and cyclosporin in combined therapy
IT1303736B1 (it) * 1998-11-11 2001-02-23 San Raffaele Centro Fond Peptidi derivati da rantes con attivita' anti-hiv.
AU3269399A (en) * 1999-03-22 2000-10-09 Universitat Zurich Transforming growth factor (tfg) beta superfamily antagonists
US20030191291A1 (en) 2000-09-08 2003-10-09 Kochendoerfer Gerd G. Synthetic erythropoiesis stimulating proteins
US8153121B2 (en) * 2000-10-06 2012-04-10 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
US7998681B2 (en) * 2000-10-06 2011-08-16 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Diagnosis and therapy of antibody-mediated inflammatory auto-immune disorders
US20030082135A1 (en) * 2001-10-30 2003-05-01 Dorf Martin E. Pathway of RANTES-mediated chemokine synthesis in astrocytes and methods of use therefor
WO2003051921A1 (en) * 2001-12-17 2003-06-26 Applied Research Systems Ars Holding N.V. Chemokine mutants acting as chemokine antagonists
US20040191215A1 (en) * 2003-03-25 2004-09-30 Michael Froix Compositions for induction of a therapeutic response
US7390788B2 (en) * 2005-06-23 2008-06-24 Pert Candace B Peptide pharmaceutical compositions
WO2008015199A1 (en) * 2006-07-31 2008-02-07 Laboratoires Serono S.A. Chemokine antagonists
US8012474B2 (en) * 2007-08-02 2011-09-06 Nov Immune S.A. Anti-RANTES antibodies
CA2788902C (en) 2010-02-08 2019-09-03 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same
EP2741777B1 (en) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
CN118556073A (zh) 2021-10-06 2024-08-27 维罗治疗有限公司 新型免疫调节剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU688641B2 (en) * 1994-12-08 1998-03-12 Glaxo Group Limited Rantes peptide and fragments and compositions comprising it for treatment of inflammation

Also Published As

Publication number Publication date
EP0796330A1 (en) 1997-09-24
CZ290850B6 (cs) 2002-10-16
FI972433A0 (fi) 1997-06-06
WO1996017935A3 (en) 1996-08-22
JPH10510151A (ja) 1998-10-06
MX9703889A (es) 1997-08-30
PL320565A1 (en) 1997-10-13
NZ296570A (en) 1998-11-25
FI972433L (fi) 1997-06-06
CN1087346C (zh) 2002-07-10
WO1996017935A2 (en) 1996-06-13
HUT77075A (hu) 1998-03-02
CZ171997A3 (en) 1997-11-12
AU688641B2 (en) 1998-03-12
FI972433A7 (fi) 1997-06-06
US6159711A (en) 2000-12-12
NO972620D0 (no) 1997-06-06
HU221089B1 (en) 2002-08-28
PL182786B1 (pl) 2002-02-28
AU4120896A (en) 1996-06-26
CA2207036A1 (en) 1996-06-13
NO972620L (no) 1997-08-06
US6555105B1 (en) 2003-04-29
CN1168697A (zh) 1997-12-24

Similar Documents

Publication Publication Date Title
BR9509890A (pt) Polipeptídeo sequencia de dna ou rna vetor célula hospedeira e processo para produzir um polipeptídeo
BR9609774A (pt) Sequência de dna gene quimérico vetor epa célula de planta transformada planta e processo para a construção de um gene quimérico
BR8903792A (pt) Processo para ampliacao de um fragmento de acido nucleico e conjunto para a ampliacao de um fragmento de acido nucleico
BR9101137A (pt) Metodo para a preparacao de um vetor hibrido,processo para a preparacao de uma molecula de dna,metodo para a preparacao de um hospedeiro e para a preparacao de um polipeptidio e metodo para a preparacao de psm puro
BR9508053A (pt) Construção de DNA vetor de expressão recombinante cepa de levedura e processo para a produção de uma proteina heteróloga
BR9407403A (pt) Polimerase de DNA e método para sequência de DNA e método para identificação e isolamento de polimerase de DNA
KR970002669B1 (en) Reagents and methods for modulating gene expression through rna mimicry
BR9600993A (pt) Acidos fosfonomonoéster nucléicos processo para sua preparação e seu uso
FI20050243L (fi) Stabiilia bakterisidista/läpäisevyyttä parantavaa proteiinifragmenttia koodittava DNA, vektori, isäntäsolu ja menetelmä näiden proteiinipigmenttien valmistamiseksi
DE69722176D1 (de) Verfahren zur suche nach transdominanten effektorpeptiden und rna-molekülen
BR9407874A (pt) Proteína purificada de mamiferos designada por mitosina fragmento biologicamente ativo proteina purificada de mamiferos molécula isolada de ácido nucléico vetor de expressao sistema de vetor-hospedeiro para produçao de mitosina anticorpo antimitosina e processo para produçao de mitosina
BR9609507A (pt) Processo para fabricação de queijo produto de queijo e utilização de transglutaminase
BR9709733A (pt) Construção de dna quimérico recominante e processo para seleção de linhagens
BR9406957A (pt) Sistema e processo para modelagem geométrica parameétrica aperfeiçoada
AU8162598A (en) Improved method for isolating and recovering target dna or rna molecules having a desired nucleotide sequence
BRPI9600729B8 (pt) vetor de expressão, microorganismo transgênico, processo de clonagem de um ácido nucléico e processo para preparação de uma proteína e cepa de levedura transformada
BR9306150A (pt) Endo--1,4-glucanase sequéncia de dna recombinante vetor hospedeiro transformado contendo o vetor processo para a produç o de endo- -1,4-glucanase preparaç o de enzima e uso de endo- -1,4-glucanase
PT90595A (pt) Processo para a transformacao de bacillus thuringiensis
BR9607745A (pt) Processo para produzir ácido 5-inosínico ou ácido 5' guanílico transformante dna recombinante proteina e gene
NO981322L (no) Farmas÷ytiske preparater for bruk ved nukleinsyretransfeksjon, og deres anvendelse
FI971100L (fi) Menetelmä yhdistelmä-DNA-proteiinien, plasmidien ja modifioitujen solujen tuottamiseksi
DE59712554D1 (de) Rekombinante expression von s-layer-proteinen
PT90976A (pt) Processo para a preparacao de proteinas e de acidos nucleicos
ZA9811354B (en) Novel flea epoxide hydrolase nucleic acid molecules proteins and uses thereof
PL323956A1 (en) Novel proteins, pharmaceutic agent, polynucleotidic dna compound and method of obntaining novel proteins

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements